| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1537-2995.2001.41101244.X |
| P698 | PubMed publication ID | 11606823 |
| P2093 | author name string | Holland PV | |
| MacKenzie MR | |||
| Popovsky MA | |||
| Kopko PM | |||
| Paglieroni TG | |||
| Muto KN | |||
| P2860 | cites work | Transfusion-related acute lung injury caused by an NB2 granulocyte-specific antibody in a patient with thrombotic thrombocytopenic purpura | Q33403250 |
| Transfusion-related acute lung injury. | Q33610835 | ||
| Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy | Q34306589 | ||
| The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study | Q34432820 | ||
| Fatal pulmonary hypersensitivity reaction to HL-A incompatible blood transfusion:report of a case and review of the literature | Q35064386 | ||
| Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. | Q37380265 | ||
| Reports of 355 transfusion-associated deaths: 1976 through 1985. | Q38136669 | ||
| Distinguishing immunosilent AIDS from the acute retroviral syndrome in a frequent blood donor | Q41648442 | ||
| A randomized controlled trial oftransfusion-related acute lung injury: is plasma from multiparous blood donors dangerous? | Q43556866 | ||
| A near-fatal reaction during granulocyte transfusion of a neonate | Q43564040 | ||
| Severe allergic pulmonary oedema after plasma transfusion | Q45856125 | ||
| Influence of psychological stress on immune-inflammatory variables in normal humans. Part II. Altered serum concentrations of natural anti-inflammatory agents and soluble membrane antigens of monocytes and T lymphocytes. | Q51090174 | ||
| Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. | Q53770407 | ||
| P433 | issue | 10 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 1244-1248 | |
| P577 | publication date | 2001-10-01 | |
| P1433 | published in | Transfusion | Q15758500 |
| P1476 | title | HLA class II antibodies in transfusion-related acute lung injury. | |
| P478 | volume | 41 |
| Q93145806 | A consensus redefinition of transfusion-related acute lung injury |
| Q46209047 | AABB survey of transfusion-related acute lung injury policies and practices in the United States |
| Q50783341 | Activation of polymorphonuclear neutrophils by immune complex: possible involvement in development of transfusion-related acute lung injury. |
| Q46762351 | Acute and transient decrease in neutrophil count in transfusion-related acute lung injury: cases at one hospital |
| Q49408761 | Antibodies to major histocompatibility complex class II antigens directly prime neutrophils and cause acute lung injury in a two-event in vivo rat model |
| Q54392752 | Antibodies to the HLA-A2 antigen prime neutrophils and serve as the second event in an in vitro model of transfusion-related acute lung injury. |
| Q24539030 | Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission |
| Q38447155 | Antibody-mediated transfusion-related acute lung injury; from discovery to prevention |
| Q33408363 | Approach of using established and new laboratory tests to more comprehensively investigate noninfectious and nonhemolytic transfusion reactions--along with the experience in Japan |
| Q37871065 | Clinical relevance of the HLA system in blood transfusion |
| Q53166971 | Comparative analysis of the pathological events involved in immune and non-immune TRALI models. |
| Q50541004 | Detection of granulocyte antibodies using simultaneous analysis of specific granulocyte antibodies assay (SASGA). |
| Q35628879 | Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMN-mediated damage to human pulmonary microvascular endothelial cells in a two-event in vitro model. |
| Q50556977 | Enhancement of endothelial permeability by coculture with peripheral blood mononuclear cells in the presence of HLA Class II antibody that was associated with transfusion‐related acute lung injury |
| Q51126410 | Evaluation of a new microbeads assay for granulocyte antibody detection. |
| Q34447443 | Experimental models of transfusion-related acute lung injury |
| Q33697274 | Experimental prestorage filtration removes antibodies and decreases lipids in RBC supernatants mitigating TRALI in vivo |
| Q51990513 | Flow-cytometric approach to the prompt laboratory diagnosis of TRALI: a case report. |
| Q33373786 | Generation of inflammatory cytokines and chemokines from peripheral blood mononuclear cells by HLA Class II antibody-containing plasma unit that was associated with severe nonhemolytic transfusion reactions |
| Q47741465 | HLA class II antibodies in transfusion-related acute lung injury (TRALI). A case report |
| Q50650283 | HLA-DR antibodies in transfusion-related acute lung injury (TRALI): a case report. |
| Q35925724 | Hypotension and acute pulmonary insufficiency following transfusion of autologous red blood cells during surgery: a case report and review of the literature |
| Q47850031 | Impact of a transfusion-related acute lung injury reduction strategy on apheresis platelet collections. |
| Q54351108 | Implication of transfected cell lines for the detection of alloantibodies against human neutrophil antigen-3. |
| Q34170859 | Intravenous immunoglobulin prevents murine antibody-mediated acute lung injury at the level of neutrophil reactive oxygen species (ROS) production |
| Q51688549 | Investigations into the role of anti-HLA class II antibodies in TRALI. |
| Q44212683 | Is KL-6 a serum indicator of early pulmonary fibrosis in childhood cancer patients? |
| Q40295147 | Lung microvascular endothelial cell injury caused by treatment with polymorphonuclear neutrophils and low-IgM serum: a model of transfusion-related acute lung injury |
| Q50461989 | Monitoring and reporting transfusion reactions as a quality indicator - a clinical audit. |
| Q50665720 | Ninety-six suspected transfusion related acute lung injury cases: investigation findings and clinical outcome. |
| Q33361167 | Optimizing platelet transfusion therapy |
| Q43288126 | Pentoxifylline attenuates leukoreduced stored blood-induced neutrophil activation through inhibition of mitogen-activated protein kinases |
| Q73288183 | Plasma and lipids from stored platelets cause acute lung injury in an animal model |
| Q51669794 | Possible mechanisms underlying development of transfusion-related acute lung injury: roles of anti-major histocompatibility complex class II DR antibody. |
| Q37056509 | Pulmonary complications of transfused blood components |
| Q80007234 | Pulmonary consequences of transfusion: TRALI and TACO |
| Q35737035 | Pulmonary injury from transfusion-related acute lung injury |
| Q34097476 | Rapid-Onset Acute Respiratory Distress Syndrome (ARDS) in a Patient Undergoing Metastatic Liver Resection: A Case Report and Review of the Literature |
| Q40204726 | Recurrent transfusion-related acute lung injury after a two-year interval |
| Q33812070 | Reducing blood transfusion. BMJ 's cover and headline exaggerated importance of study's findings |
| Q50698975 | Role of anti-human leucocyte antigen class II alloantibody and monocytes in development of transfusion-related acute lung injury. |
| Q46948508 | Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. |
| Q50736779 | Simultaneous five cell-lineage flow cytometric analysis system for detection of leucocyte antibodies. |
| Q47330314 | T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10. |
| Q90663269 | TACO and TRALI: biology, risk factors, and prevention strategies |
| Q51643799 | TRALI after the infusion of marrow cells in a patient with acute lymphoblastic leukemia |
| Q37399178 | TRALI--definition, mechanisms, incidence and clinical relevance |
| Q37887028 | TRALI-new challenges for histocompatibility and immunogenetics in transfusion medicine |
| Q44419950 | TRALI: correlation of antigen-antibody and monocyte activation in donor-recipient pairs |
| Q28250822 | TRALI: from diagnosis to prevention |
| Q36227474 | The Epidemiology of Transfusion-related Acute Lung Injury Varies According to the Applied Definition of Lung Injury Onset Time |
| Q33760834 | The association between red blood cell and platelet transfusion and subsequently developing idiopathic pneumonia syndrome after hematopoietic stem cell transplantation |
| Q37854505 | The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists |
| Q36753034 | The pathogenesis of transfusion-related acute lung injury (TRALI). |
| Q37013555 | The pathogenesis of transfusion-related acute lung injury and how to avoid this serious adverse reaction of transfusion |
| Q34118409 | The role of neutrophils in the pathogenesis of transfusion-related acute lung injury. |
| Q38012503 | Therapeutic options for transfusion related acute lung injury; the potential of the G2A receptor |
| Q86499591 | Transfusing common sense instead of blood products into coagulation testing in patients with cirrhosis: Overtreatment ≠ safety |
| Q35812945 | Transfusion and the lung: circulatory overload and acute lung injury |
| Q36049715 | Transfusion reactions: newer concepts on the pathophysiology, incidence, treatment, and prevention of transfusion-related acute lung injury |
| Q34986818 | Transfusion-Related Acute Lung Injury (TRALI): Report of 2 Cases and a Review of The Literature |
| Q34791015 | Transfusion-Related Acute Lung Injury: Incidence, Pathogenesis and the Role of Multicomponent Apheresis in Its Prevention |
| Q45058712 | Transfusion-related acute lung injury |
| Q79192198 | Transfusion-related acute lung injury |
| Q80636012 | Transfusion-related acute lung injury |
| Q80113052 | Transfusion-related acute lung injury (TRALI)--an important, severe transfusion-related complication |
| Q35940036 | Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. |
| Q28254823 | Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion |
| Q35100910 | Transfusion-related acute lung injury (TRALI): current concepts and misconceptions. |
| Q50692594 | Transfusion-related acute lung injury and leucocyte-reacting antibodies. |
| Q36054831 | Transfusion-related acute lung injury in the Canadian paediatric population |
| Q36603315 | Transfusion-related acute lung injury in the paediatric patient: Two case reports and a review of the literature |
| Q47628286 | Transfusion-related acute lung injury risk mitigation: an update |
| Q38017398 | Transfusion-related acute lung injury: Current understanding and preventive strategies |
| Q38104081 | Transfusion-related acute lung injury: a clinical review |
| Q36546623 | Transfusion-related acute lung injury: a literature review |
| Q37978345 | Transfusion-related acute lung injury: a preventable syndrome? |
| Q38115585 | Transfusion-related acute lung injury: advances in understanding the role of proinflammatory mediators in its genesis |
| Q37810127 | Transfusion-related acute lung injury: emerging importance of host factors and implications for management |
| Q35777001 | Transfusion-related acute lung injury: incidence and risk factors. |
| Q47722853 | White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. |
| Q83841178 | [Pulmonary complications of transfusion (TACO-TRALI)] |
| Q81798893 | [TRALI] |
Search more.